CN114867720A - 杂芳基类衍生物及其制备方法和用途 - Google Patents

杂芳基类衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN114867720A
CN114867720A CN202180007547.2A CN202180007547A CN114867720A CN 114867720 A CN114867720 A CN 114867720A CN 202180007547 A CN202180007547 A CN 202180007547A CN 114867720 A CN114867720 A CN 114867720A
Authority
CN
China
Prior art keywords
group
amino
pyrazolo
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180007547.2A
Other languages
English (en)
Inventor
黄贤贵
郭阳辉
仇宗兴
别平彦
廖伟伟
晏青燕
沈卫超
曹海
邢庆娜
王鑫
曹琪
孟力陈
吴诺毅
李文朋
叶成
胡泰山
陈磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd, Shanghai Aryl Pharmtech Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN114867720A publication Critical patent/CN114867720A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明涉及杂芳基类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式(AI)所示的杂芳基类衍生物、其制备方法及其可药用的盐，以及它们作为治疗剂，特别是SHP2变构抑制剂的用途，其中通式(AI)中的各取代基的定义与说明书中的定义相同

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202180007547.2A 2020-01-16 2021-01-12 杂芳基类衍生物及其制备方法和用途 Pending CN114867720A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010046221 2020-01-16
CN2020100462218 2020-01-16
CN2020106605198 2020-07-10
CN202010660519 2020-07-10
PCT/CN2021/071297 WO2021143680A1 (zh) 2020-01-16 2021-01-12 杂芳基类衍生物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN114867720A true CN114867720A (zh) 2022-08-05

Family

ID=76863563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180007547.2A Pending CN114867720A (zh) 2020-01-16 2021-01-12 杂芳基类衍生物及其制备方法和用途

Country Status (5)

Country Link
US (1) US20230348467A1 (zh)
EP (1) EP4092019A4 (zh)
JP (1) JP7392164B2 (zh)
CN (1) CN114867720A (zh)
WO (1) WO2021143680A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
WO2022235864A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors
KR20240017811A (ko) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. 암의 치료를 위한 ras 억제제
CN115340545A (zh) * 2021-05-14 2022-11-15 浙江海正药业股份有限公司 双环杂芳基类衍生物及其制备方法和用途
KR20240055778A (ko) 2021-09-01 2024-04-29 노파르티스 아게 Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN114213255A (zh) * 2021-12-29 2022-03-22 上海泰坦科技股份有限公司 一种六元环苄胺类化合物的合成方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Ｍｅｋ抑制劑及其用途
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203404A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2017156397A1 (en) * 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
CN110143949A (zh) * 2018-05-09 2019-08-20 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
WO2019165073A1 (en) * 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2019182960A1 (en) * 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161439A0 (en) 2001-11-14 2004-09-27 Schering Corp Cannabinoid receptor ligands
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
EP3359527A1 (en) 2015-10-07 2018-08-15 H. Hoffnabb-La Roche Ag Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
MX2018015625A (es) 2016-06-14 2019-03-06 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
MX2019000548A (es) 2016-07-12 2019-10-30 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
WO2019169153A1 (en) 2018-03-01 2019-09-06 Takeda Pharmaceutical Company Limited Piperidinyl-3-(aryloxy)propanamides and propanoates
WO2019183364A1 (en) * 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203404A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2017156397A1 (en) * 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
WO2019165073A1 (en) * 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2019182960A1 (en) * 2018-03-21 2019-09-26 Synblia Therapeutics, Inc. Shp2 inhibitors and uses thereof
CN110143949A (zh) * 2018-05-09 2019-08-20 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物

Also Published As

Publication number Publication date
JP2023510929A (ja) 2023-03-15
JP7392164B2 (ja) 2023-12-05
WO2021143680A1 (zh) 2021-07-22
EP4092019A1 (en) 2022-11-23
EP4092019A4 (en) 2024-02-28
US20230348467A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
CN114867720A (zh) 杂芳基类衍生物及其制备方法和用途
CN113396147A (zh) 芳香杂环类衍生物调节剂、其制备方法和应用
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
TW202039498A (zh) 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN115353509A (zh) 含氮杂芳类衍生物调节剂、其制备方法和应用
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
CN111285886B (zh) 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
KR20190140931A (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
US20160024007A1 (en) Octahydrocyclopentapyrroles, their preparation and use
JP2023528903A (ja) Ｋｒａｓ ｇ１２ｃタンパク質阻害剤およびその使用
CN114761394A (zh) 吡啶或嘧啶类衍生物及其制备方法和用途
WO2015158310A1 (zh) 一种酪氨酸激酶抑制剂及其用途
TW201625619A (zh) 抑制瞬態電位受器ａ１離子通道
CN114341127A (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
WO2022007869A1 (zh) 吡啶或嘧啶类衍生物及其制备方法和用途
WO2021197452A1 (zh) 含氮杂芳类衍生物自由碱的晶型
CN114835687B (zh) AhR抑制剂
TW202241906A (zh) 吲唑化合物
CN115867346A (zh) 激酶抑制剂
TWI818424B (zh) 含氮多環稠環類化合物，其藥物組合物、製備方法和用途
WO2022237178A1 (zh) 双环杂芳基类衍生物及其制备方法和用途
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
WO2021249417A1 (zh) 杂环化合物及其衍生物
TW202112783A (zh) 三環類化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40070593

Country of ref document: HK